Drug intelligence / Profile preview

TAK-004

Development stage: Phase 1
Lead developer: Takeda
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

TAK-004 is an investigational vaccine developed by Takeda for subcutaneous administration. It is currently being evaluated in a first-in-human, Phase 1 clinical trial to assess its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult volunteers. The specific disease target or indication for TAK-004 has not been publicly disclosed as of the latest available information. The study involves single or multiple doses administered via subcutaneous injection and includes monitoring of adverse events and immune response.

Targets

NS1 (Zika virus nonstructural protein 1)E (Tick-borne encephalitis virus envelope protein)

Beyond the preview

Go deeper on TAK-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-004.

Explore the full profile